Mal-Val-Ala-PAB-N(SO2Me)-Exatecan
Based on 1 Customer Validation
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer.
For research use only. We do not sell to patients.
- Purity: 98.84%
- CAS No.: 2575682-08-3
- Formula: C56H65FN8O15S
- Molecular Weight:1141.22
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2575682-08-3
-
Appearance Solid
-
Molecular Weight 1141.22
-
Formula C56H65FN8O15S
-
Color White to yellow
-
SMILES
O=C(C=CC1=O)N1CCCCCC(N[C@@H](C(C)C)C(N[C@@H](C)C(NC(C=C2)=CC=C2COC(N(CCS(C)(=O)=O)COCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : ≥ 100 mg/mL (87.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Guo Q, et al., FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28. [Content Brief]
[2]. Liu N, et al., Preparation method of linker drug conjugate and intermediate thereof. CN116178386.
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8763 mL | 4.3813 mL | 8.7626 mL | 21.9064 mL |
| 5 mM | 0.1753 mL | 0.8763 mL | 1.7525 mL | 4.3813 mL | |
| 10 mM | 0.0876 mL | 0.4381 mL | 0.8763 mL | 2.1906 mL | |
| 15 mM | 0.0584 mL | 0.2921 mL | 0.5842 mL | 1.4604 mL | |
| 20 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 1.0953 mL | |
| 25 mM | 0.0351 mL | 0.1753 mL | 0.3505 mL | 0.8763 mL | |
| 30 mM | 0.0292 mL | 0.1460 mL | 0.2921 mL | 0.7302 mL | |
| 40 mM | 0.0219 mL | 0.1095 mL | 0.2191 mL | 0.5477 mL | |
| 50 mM | 0.0175 mL | 0.0876 mL | 0.1753 mL | 0.4381 mL | |
| 60 mM | 0.0146 mL | 0.0730 mL | 0.1460 mL | 0.3651 mL | |
| 80 mM | 0.0110 mL | 0.0548 mL | 0.1095 mL | 0.2738 mL |
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan Related Classifications
HY-159072 Related Classifications
Powered by Bioz